Real World Effectiveness of Atezolizumab and Bevacizumab: What Lessons Can We Learn?

Overview

Journal J Clin Exp Hepatol

Publisher Elsevier

Specialty Gastroenterology

Date 2023 Jul 13

PMID 37440937

Authors

Aparna Kalyan

Amit Singal

Affiliations

Soon will be listed here.

References

Marrero J, Kudo M, Venook A, Ye S, Bronowicki J, Chen X . Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. J Hepatol. 2016; 65(6):1140-1147. DOI: 10.1016/j.jhep.2016.07.020. View

Espinoza M, Muquith M, Lim M, Zhu H, Singal A, Hsiehchen D . Disease Etiology and Outcomes After Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: Post-Hoc Analysis of IMbrave150. Gastroenterology. 2023; 165(1):286-288.e4. DOI: 10.1053/j.gastro.2023.02.042. View

Fulgenzi C, Cheon J, DAlessio A, Nishida N, Ang C, Marron T . Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study. Eur J Cancer. 2022; 175:204-213. DOI: 10.1016/j.ejca.2022.08.024. View

Pfister D, Gonzalo Nunez N, Pinyol R, Govaere O, Pinter M, Szydlowska M . NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021; 592(7854):450-456. PMC: 8046670. DOI: 10.1038/s41586-021-03362-0. View

Reig M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, Garcia-Criado A . BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2021; 76(3):681-693. PMC: 8866082. DOI: 10.1016/j.jhep.2021.11.018. View

Finn R, Qin S, Ikeda M, Galle P, Ducreux M, Kim T . Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020; 382(20):1894-1905. DOI: 10.1056/NEJMoa1915745. View

Singal A, Higgins P, Waljee A . A primer on effectiveness and efficacy trials. Clin Transl Gastroenterol. 2014; 5:e45. PMC: 3912314. DOI: 10.1038/ctg.2013.13. View

Rich N, Hester C, Odewole M, Murphy C, Parikh N, Marrero J . Racial and Ethnic Differences in Presentation and Outcomes of Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2018; 17(3):551-559.e1. PMC: 6274621. DOI: 10.1016/j.cgh.2018.05.039. View

Llovet J, Kelley R, Villanueva A, Singal A, Pikarsky E, Roayaie S . Hepatocellular carcinoma. Nat Rev Dis Primers. 2021; 7(1):6. DOI: 10.1038/s41572-020-00240-3. View

10.

Huang D, Singal A, Kono Y, Tan D, El-Serag H, Loomba R . Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metab. 2022; 34(7):969-977.e2. PMC: 9762323. DOI: 10.1016/j.cmet.2022.05.003. View

11.

Cheng A, Qin S, Ikeda M, Galle P, Ducreux M, Kim T . Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2021; 76(4):862-873. DOI: 10.1016/j.jhep.2021.11.030. View

12.

Stemmer S, Manojlovic N, Marinca M, Petrov P, Cherciu N, Ganea D . Namodenoson in Advanced Hepatocellular Carcinoma and Child-Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial. Cancers (Basel). 2021; 13(2). PMC: 7825785. DOI: 10.3390/cancers13020187. View

13.

Kulkarni A, Krishna V, Kumar K, Sharma M, Patodiya B, Khan A . Safety and Efficacy of Atezolizumab-Bevacizumab in Real World: The First Indian Experience. J Clin Exp Hepatol. 2023; 13(4):618-623. PMC: 10333935. DOI: 10.1016/j.jceh.2023.02.003. View

14.

Kudo M, Matilla A, Santoro A, Melero I, Gracian A, Acosta-Rivera M . CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. J Hepatol. 2021; 75(3):600-609. DOI: 10.1016/j.jhep.2021.04.047. View

15.

Watanabe Y, Aikawa M, Kato T, Takase K, Watanabe Y, Okada K . Influence of Child-Pugh B7 and B8/9 cirrhosis on laparoscopic liver resection for hepatocellular carcinoma: a retrospective cohort study. Surg Endosc. 2022; 37(2):1316-1333. PMC: 9540096. DOI: 10.1007/s00464-022-09677-x. View

16.

Johnson P, Pinato D, Kalyuzhnyy A, Toyoda H . Breaking the Child-Pugh Dogma in Hepatocellular Carcinoma. J Clin Oncol. 2022; 40(19):2078-2082. DOI: 10.1200/JCO.21.02373. View

17.

Kelley R . Atezolizumab plus Bevacizumab - A Landmark in Liver Cancer. N Engl J Med. 2020; 382(20):1953-1955. DOI: 10.1056/NEJMe2004851. View

18.

DAlessio A, Fulgenzi C, Nishida N, Schonlein M, von Felden J, Schulze K . Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study. Hepatology. 2022; 76(4):1000-1012. PMC: 9790703. DOI: 10.1002/hep.32468. View

19.

de Castro T, Jochheim L, Bathon M, Welland S, Scheiner B, Shmanko K . Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience. Ther Adv Med Oncol. 2022; 14:17588359221080298. PMC: 8891886. DOI: 10.1177/17588359221080298. View

20.

Haber P, Puigvehi M, Castet F, Lourdusamy V, Montal R, Tabrizian P . Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020). Gastroenterology. 2021; 161(3):879-898. DOI: 10.1053/j.gastro.2021.06.008. View